Last reviewed · How we verify
Intermitent Dosing
Intermitent Dosing, marketed by the Community Research Initiative of New England, holds a niche position in its therapeutic segment. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market presence. However, the lack of disclosed revenue and primary trial results poses a significant risk in assessing its long-term commercial viability and competitive edge.
At a glance
| Generic name | Intermitent Dosing |
|---|---|
| Sponsor | Community Research Initiative of New England |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients (PHASE4)
- FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment (PHASE4)
- Tranexamic Acid (TXA) in Pediatric Cardiac Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |